BCAB is no longer listed. Its last trade on record was Sep 24, 2026. The price and figures on this page are from its last trading day and final filings, and are no longer updated.
BCAB trades 16347.4% below Wall Street's consensus target of $250.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes BCAB achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, BioAtla, Inc. (BCAB) has a Wall Street consensus price target of $250.00, based on estimates from 9 covering analysts.
Analyst price targets range from a low of $250.00 to a high of $250.00, representing a 0% spread in expectations. The median target of $250.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, BCAB trades at a. Analysts expect EPS to grow -143.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $6.3B | $30.53 | $40.00 | +31.0% | Buy | — | 23 |
 RCUSArcus Biosciences, Inc. | $2.3B | $18.28 | $38.80 | +112.3% | Buy | — | 18 |
 AGENAgenus Inc. | $298M | $7.15 | $25.00 | +249.7% | Buy | 26.7x | 12 |
 MGNXMacroGenics, Inc. | $148M | $2.33 | $9.78 | +319.7% | Buy | — | 22 |
 FATEFate Therapeutics, Inc. | $214M | $1.84 | $5.63 | +206.8% | Buy | — | 31 |
 MIRMMirum Pharmaceuticals, Inc. | $5.7B | $93.72 | $155.80 | +66.2% | Buy | — | 18 |
 ARVNArvinas, Inc. | $414M | $6.41 | $14.00 | +118.4% | Buy | 90.0x | 26 |
 NKTRNektar Therapeutics | $1.2B | $37.26 | $121.33 | +225.6% | Buy | — | 33 |
 AGIOAgios Pharmaceuticals, Inc. | $1.7B | $29.41 | $40.67 | +38.3% | Buy | — | 29 |
 REGNRegeneron Pharmaceuticals, Inc. | $93.2B | $904.35 | $887.79 | -1.8% | Buy | 13.4x | 49 |
Quick answers to the most common questions about buying BCAB stock.
The consensus Wall Street price target for BCAB is $250, representing 16347.4% upside from the current price of $N/A. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BCAB has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $250 implies 16347.4% upside from current levels.
BCAB's current price is $N/A with a consensus target of $250 (16347.4% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $250 for BCAB, while the most conservative target is $250. The consensus of $250 represents the median expectation. These targets typically reflect 12-month expectations.
BCAB is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BCAB stock forecast based on 9 Wall Street analysts shows a consensus price target of $250, with estimates ranging from $250 (bear case) to $250 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on BCAB, with a "Buy" consensus rating and $250 price target (16347.4% upside). 6 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BCAB analyst price targets range from $250 to $250, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $250 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.